<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985062</url>
  </required_header>
  <id_info>
    <org_study_id>VPG.03.02</org_study_id>
    <nct_id>NCT00985062</nct_id>
  </id_info>
  <brief_title>Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization</brief_title>
  <acronym>FOLFO</acronym>
  <official_title>Food Lifestyle and Fertility Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vitro fertilization (IVF) is an assisted reproductive technique to achieve pregnancy in
      subfertile couples of which the average success rate is only 25%. Mild ovarian stimulation
      treatment yields less oocytes, has less adverse effects but has a comparable clinical outcome
      compared to conventional stimulation treatment. There is high inter- and intra person
      variability in ovarian response and fertility outcome parameters after stimulation treatment
      and little is known about explanatory variables herefore.

      Nutrition and in particular folate, or its synthetic derivative folic acid, is a B-vitamin
      which has been widely asssociated with reproductive outcome and subfertility. Therefore, in
      this study we aim to investigate the influence of preconception nutrition and folic acid use
      on ovarian response after mild/conventional stimulation treatment and to identify biomarkers
      in the follicular fluid which can indicate oocyte quality and other fertility outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endocrine, metabolic biomarkers and proteins and Fertility outcome parameters</measure>
    <time_frame>At menstrual cycle day 2 before stimulation, on the day of hCG administration after stimulation treatment and after embryo transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Homocysteine-methionine cycle biomarker, endocrine and folate levels in serum</measure>
    <time_frame>At menstrual cycle day 2 before stimulation and on the day of hCG administration after stimulation treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Mild Ovarian Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Ovarian Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mild Ovarian Stimulation Treatment</intervention_name>
    <description>Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.</description>
    <arm_group_label>Mild Ovarian Stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Ovarian Stimulation Treatment</intervention_name>
    <description>Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered</description>
    <arm_group_label>Conventional Ovarian Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All couples with an indication for IVF/ICSI treatment in the Erasmus Medical Center

        Exclusion Criteria:

          -  Prior oocyte donation

          -  Endometriosis

          -  Hydrosalpinx

          -  MESA/PESA

          -  Age &gt;37

          -  BMI &lt;18 or &gt;29kg/m2

          -  Menstrual cycle disruptions

          -  Indication for Intra Cytoplasmic Sperm Injection (ICSI)

          -  Prior IVF treatment without embryo transplant

          -  History of recurrent abortion

          -  Abnormal karyotype of male/female

          -  Uterine abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Forges T, Pellanda H, Diligent C, Monnier P, Guéant JL. [Do folates have an impact on fertility?]. Gynecol Obstet Fertil. 2008 Sep;36(9):930-9. doi: 10.1016/j.gyobfe.2008.07.004. Epub 2008 Aug 12. Review. French.</citation>
    <PMID>18701335</PMID>
  </reference>
  <reference>
    <citation>Fauser BC, Diedrich K, Devroey P; Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008 Jan-Feb;14(1):1-14. Epub 2007 Nov 15. Review.</citation>
    <PMID>18006561</PMID>
  </reference>
  <reference>
    <citation>Verberg MF, Eijkemans MJ, Macklon NS, Heijnen EM, Baart EB, Hohmann FP, Fauser BC, Broekmans FJ. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update. 2009 Jan-Feb;15(1):5-12. doi: 10.1093/humupd/dmn053. Review.</citation>
    <PMID>19091754</PMID>
  </reference>
  <reference>
    <citation>Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ, Fauser BC. Mild ovarian stimulation for IVF. Hum Reprod Update. 2009 Jan-Feb;15(1):13-29. doi: 10.1093/humupd/dmn056. Review.</citation>
    <PMID>19091755</PMID>
  </reference>
  <results_reference>
    <citation>Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A, Macklon NS, Fauser BC. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod. 2007 Apr;22(4):980-8. Epub 2007 Jan 4.</citation>
    <PMID>17204525</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <last_update_submitted>September 25, 2009</last_update_submitted>
  <last_update_submitted_qc>September 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. R.P.M. Steegers-Theunissen</name_title>
    <organization>Erasmus Medical Center</organization>
  </responsible_party>
  <keyword>Folic Acid</keyword>
  <keyword>Homocysteine</keyword>
  <keyword>Ovarian response</keyword>
  <keyword>In Vitro Fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

